Top-line data from all patients on the primary endpoint of Kiadis Pharma’s Phase II trial with ATIR101TM selected for oral presentation at 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation

~ Additional ATIR101TM data also selected for three poster presentations at EBMT ~

Amsterdam, The Netherlands, March 1, 2016, – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that key data from the Company’s ongoing single-dose Phase II clinical trial (NCT01794299/EudraCT 2012-004461- 41) with its lead product ATIR101TM has been selected for an oral presentation to discuss the top-line data at the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on April 3-6, 2016 in Valencia, Spain. Three abstracts on additional ATIR101TM data and the ATIR101TM development program have also been accepted for poster presentations at EBMT.
The oral presentation entitled ‘Donor lymphocytes depleted of alloreactive T-cells (ATIR101) improve overall survival and reduce transplant related mortality in a T-cell depleted haploidentical HSCT: Results from a Phase 2 Trial in patients with AML and ALL’ will be delivered in Room B6 on Monday April 4, 2016 at 16:05 CET by Dr. Denis-Claude Roy, Professor of Medicine at the University of Montreal and principal investigator for the study.
The presentation will include the full dataset on the primary endpoint of the study (Transplant Related Mortality at six months post transplantation) which will also be put into perspective with other current approaches in the literature for patients lacking a fully matched donor, such as the Baltimore approach using post-transplant cyclophosphamide.

Oral and poster presentations at EBMT:

Oral Presentation

Monday April 4, 2016 at 16:05 CET (Room B6)
Title: Donor lymphocytes depleted of alloreactive T-cells (ATIR101) improve overall survival and reduce transplant related mortality in a T-cell depleted haploidentical HSCT: Results from a Phase 2 Trial in patients with AML and ALL.
Presenting author: Denis-Claude Roy

Poster Presentations

Monday April 4, 2016 from 17:15-19:00 CET, Poster Area
– P020: Title: Leukemia-associated antigen reactive T-cells in ATIR101, a recipient-specific
allodepleted T-cell product facilitating haploidentical HSCT.
Presenting author: Jurjen Velthuis

Tuesday April 5, 2016 from 17:15-19:00 CET, Poster Area
– P442: Title: Effect of graft source on safety and efficacy in patients undergoing
hematopoietic stem cell transplantation.
Presenting author: Stephan Mielke

– P462: Title: An exploratory, open-label, multicenter study to evaluate safety and efficacy of a two-dose regimen of ATIR101 in patients with a hematologic malignancy, who received a CD34-selected hematopoietic stem cell transplantation from a haploidentical donor.
Presenting author: Stephan Mielke

Full abstracts will be made available on the EBMT website (http://www.ebmt2016.org/abstracts.html) but data presented during the oral presentation will contain additional data that was not yet available at the time of abstract submission.

Leave a comment

Your email address will not be published.